» Articles » PMID: 33304714

Data Resource Profile: JMDC Claims Databases Sourced from Medical Institutions

Overview
Journal J Gen Fam Med
Specialty Public Health
Date 2020 Dec 11
PMID 33304714
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

JMDC, Inc. (JMDC) has created a database, using data collected from medical institutions in Japan, consisting of claims (for hospitalization and outpatient treatment), diagnosis procedure combination (DPC) assessment forms, and clinical laboratory test values. The oldest data in this database that can be accessed relate to treatment in April 2014. Currently (the end of October 2019), the number of medical institutions is 218, consisting of 131 DPC-eligible hospitals and 87 DPC-ineligible hospitals. Using this database, it is possible to carry out an analysis that makes up for certain limitations of JMDC's another database of data from health insurance societies (eg, the disease status and test results cannot be ascertained, and there is insufficient access to data for elderly people). In addition, it is noteworthy that this database includes not only data from DPC-eligible hospitals but also data from some DPC-ineligible hospitals.

Citing Articles

Changes in surgical versus nonsurgical treatments for gastrointestinal cancers during the COVID-19 pandemic: a nationwide analysis in Japan.

Seishima R, Hibi T, Takeuchi M, Takemura Y, Maeda H, Kondo M Surg Today. 2025; .

PMID: 40032678 DOI: 10.1007/s00595-025-03021-1.


Trends in Kampo Medicine Usage as Supportive Care During Anticancer Drug Treatment in Japanese Patients: A Nationwide Cohort Analysis from Fiscal Years 2015 to 2021.

Ohta H, Yasu T Curr Oncol. 2025; 32(2).

PMID: 39996900 PMC: 11854802. DOI: 10.3390/curroncol32020100.


Impact of Delayed Postoperative Rehabilitation on Patients with Valvular Heart Disease: A Retrospective Cohort Study.

Ochiai K, Kameda I, Kato Y, Shimizu M, Momosaki R Prog Rehabil Med. 2025; 10:20250006.

PMID: 39989475 PMC: 11840441. DOI: 10.2490/prm.20250006.


Impact of the COVID-19 pandemic on utilization of mental health services among children and adolescents using an interrupted time series analysis.

Endo F, Hiramatsu Y, Ide H Sci Rep. 2025; 15(1):2411.

PMID: 39827324 PMC: 11742983. DOI: 10.1038/s41598-025-87072-x.


Author response to: OSIN-D-24-01586, "Revisiting the safety of romosozumab in Japan: the need for clear contraindications for patients with cardiovascular risk".

Masuda S, Fukasawa T, Matsuda S, Yoshida S, Kawakami K Osteoporos Int. 2025; 36(3):565-567.

PMID: 39777490 DOI: 10.1007/s00198-024-07348-2.


References
1.
Ito Y, Van Schyndle J, Nishimura T, Sugitani T, Kimura T . Characteristics of Patients with Diabetes Initiating Sodium Glucose Co-transporter-2 Inhibitors (SGLT2i): Real-World Results from Three Administrative Databases in Japan. Diabetes Ther. 2019; 10(2):549-562. PMC: 6437244. DOI: 10.1007/s13300-019-0577-7. View

2.
Kimura S, Sato T, Ikeda S, Noda M, Nakayama T . Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol. 2010; 20(5):413-9. PMC: 3900837. DOI: 10.2188/jea.je20090066. View

3.
Nagai K, Tanaka T, Kodaira N, Kimura S, Takahashi Y, Nakayama T . Data resource profile: JMDC claims databases sourced from Medical Institutions. J Gen Fam Med. 2020; 21(6):211-218. PMC: 7689231. DOI: 10.1002/jgf2.367. View

4.
Nishioka S, Wakabayashi H, Maeda K, Shamoto H, Taketani Y, Kayashita J . Body mass index and recovery of activities of daily living in older patients with femoral fracture: An analysis of a national inpatient database in Japan. Arch Gerontol Geriatr. 2020; 87:104009. DOI: 10.1016/j.archger.2020.104009. View

5.
Ito Y, Van Schyndle J, Nishimura T, Sugitani T, Kimura T . Drug Utilization Patterns in Patients with Diabetes Initiating Sodium Glucose Co-Transporter-2 Inhibitors (SGLT2i) in Japan: A Multi-Database Study (2014-2017). Diabetes Ther. 2019; 10(6):2233-2249. PMC: 6848432. DOI: 10.1007/s13300-019-00710-2. View